The pharmacokinetic and pharmacodynamic interaction between propafenone and lidocaine.
Although propafenone is a known substrate and inhibitor of the cytochrome P450 4-hydroxylation pathway of debrisoquin (CYP2D6 isozyme), its effects on other hepatic mixed- function oxidative isozymes have not been extensively evaluated. We studied the influence of propafenone on the disposition of continuously infused lidocaine in 12 healthy male volunteers. Placebo or propafenone (225 mg every 8 hours) was orally administered for 4 days before and during lidocaine administration (2 mg/kg/hr for 22 hours). In the 11 (92%) subjects phenotyped as extensive metabolizers, propafenone significantly increased the lidocaine area under the plasma concentration time curve (81.7 +/- 16.2 versus 76.3 +/- 15.6 micrograms.hr/ml; p < or = 0.05) and reduced systemic lidocaine clearance (9.53 +/- 1.77 versus 10.27 +/- 2.24 ml/min/kg; p < or = 0.05), but did not significantly affect volume of distribution at steady state (2.48 +/- 0.33 versus 2.64 +/- 0.45 L/kg; p = 0.10) or mean residence time (4.37 +/- 0.92 versus 4.47 +/- 0.87 hours; difference not significant) compared with placebo, respectively. Adverse central nervous system effects were significantly worse in severity and duration during the propafenone phase (p < or = 0.05). Propafenone minimally inhibits the metabolism of lidocaine. This suggests that the ability of propafenone to inhibit metabolic pathways exclusive of the CYP2D6 isozyme may be limited. In addition, potentiation of disturbing central nervous system adverse effects may occur during combination therapy of propafenone and lidocaine.
Ujhelyi
M R
MR
School of Pharmacy, University of Connecticut, Stors.
O'Rangers
E A
EA
Fan
C
C
Kluger
J
J
Pharand
C
C
Chow
M S
MS
D000328:Adult; D001794:Blood Pressure / Q000187:drug effects; D004347:Drug Interactions; D004562:Electrocardiography / Q000187:drug effects; D006801:Humans; D007262:Infusions, Intravenous; D008012:Lidocaine / Q000097:blood / Q000378:metabolism / Q000493:pharmacokinetics*; D008297:Male; D010641:Phenotype; D011405:Propafenone / Q000378:metabolism / Q000493:pharmacokinetics / Q000494:pharmacology*; D011897:Random Allocation; D012044:Regression Analysis
D011405:Propafenone; D008012:Lidocaine